Gabriele Multhoff, PhD

Dr. Gabriele Multhoff is Professor of Experimental Radiation Oncology and Radiobiology in the Department of Radiation Oncology at the Technische Universität München (TUM) and Head of the Radiation Immuno-Oncology Research Group at the TranslaTUM – Central Institute for Translational Cancer Research at TUM, Munich, Germany.

Gabriele Multhoff is also Founder, former CEO and current CSO of Multimmune GmbH, Munich, Germany, a private clinical-stage biopharmaceutical company. For more than 25 years, Gabriele Multhoff has focused on the development of innovative NK cell-based immunotherapies, therapeutic antibodies and targeting nanoparticles based on the selective expression of membrane heat shock protein 70 (Hsp70) on tumor cells, a concept which she discovered.

In 2002 she became a Professor of Experimental Hematology at the University Hospital Regensburg. During this time she successfully delivered a Phase I clinical study evaluating the safety and efficacy of Hsp70 peptide (TKD)/IL-2 activated natural killer (NK) cells in patients with advanced colorectal and non small cell lung cancer (NSCLC).

At the TU München, Gabriele Multhoff initiated a proof-of-concept phase II clinical trial to evaluate an NK cell mediated immunotherapeutic approach to improve the clinical outcome of patients with NSCLC following radio(chemo)therapy.

Gabriele Multhoff’s research group continues to identify tumor-specific biomarkers for multimodal tumor imaging and theranostic purposes. Gabriele Multhoff has over 200 papers in peer-reviewed journals and is a named inventor on multiple filed and granted patents.